In summary, FGF4 exhibits a significant mitigating effect on high-glucose-induced lung cell damage through the AMPK-PGC-1 signaling axis, providing a new strategy for the treatment of diabetes and its pulmonary complications. Here, PPARGC1A is linked to diabetes mellitus.